In the R1LWT SQ murine HCC model, intratumoral administration of MMR combined with antibodies that block PD-1 and CTLA-4 (i.e., triple-combination therapy) suppressed tumor growth and reprogrammed the TME by enhancing CTL infiltration, reducing PD-1+ exhausted T cells, and polarizing TAMs. The gene discussed is CTLA4; the disease is neoplasm.